Daewoong Pharmaceutical Co., Ltd. is a leading South Korean global healthcare group dedicated to improving the quality of life through innovative RD and world-class manufacturing. Since its founding in 1945, Daewoong has evolved into a powerhouse in the cardiovascular and metabolic sectors.

With a strong focus on the CV pipeline, Daewoong offers a comprehensive portfolio of statin-based therapies, including Litovazet Atorvastatin + Ezetimibe, providing effective solutions for dyslipidemia and atherosclerosis. Our commitment to cardiovascular health is further demonstrated through continuous clinical research and the development of next-generation combination therapies like Baro Ezet.

Driven by the vision of becoming a "Global Healthcare Group that contributes to the improvement of quality of life," Daewoong Pharmaceutical actively engages with the global medical community at TCTAP to share clinical insights and advance interventional cardiology.